Pazopanib: all 220 studies that test it
Page 2 of 3. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.
- Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal CancerCompletedNCT00454142Phase 2Results posted
- Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell CancerCompletedNCT00387764Phase 3Results posted
- Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung CancerCompletedNCT00367679Phase 2Results posted
- Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant GliomaCompletedNCT00350727Phase 2Results posted
- Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast CancerCompletedNCT00347919Phase 2Results posted
- Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell CarcinomaCompletedNCT00334282Phase 3Results posted
- Pazopanib In Patients With Relapsed Or Refractory Soft Tissue SarcomaCompletedNCT00297258Phase 2Results posted
- A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian CancerCompletedNCT00281632Phase 2Results posted
- GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell CarcinomaCompletedNCT00244764Phase 2Results posted
- HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue SarcomasActive, not recruitingNCT05180695Phase 1/2
- Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIbCompletedNCT04462445Phase 2
- Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)Active, not recruitingNCT03850964Phase 2/3
- A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue SarcomaCompletedNCT03798106Phase 2
- Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of GlioblastomaWithdrawnNCT03275558Phase 1
- Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue SarcomasWithdrawnNCT03149120Phase 2
- PAZIT Study for Children and Young Adults With Relapsed or Refractory SarcomaCompletedNCT03139331Phase 1
- A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney CancerCompletedNCT02960906Phase 2
- Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid TumorsCompletedNCT02691767Not applicable
- Genomics-Based Target Therapy for Children With Relapsed or Refractory MalignancyStatus unknownNCT02638428Phase 2
- Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma PatientsTerminatedNCT02575066Phase 2
- Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell CarcinomaCompletedNCT02555748Phase 4
- Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid TumorsCompletedNCT02450136Not applicable
- Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland CarcinomaCompletedNCT02393820Phase 2
- Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian CancerCompletedNCT02383251Phase 2
- Pazopanib for Treating Uterine LeiomyosarcomaWithdrawnNCT02378142Phase 2
- Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue SarcomaWithdrawnNCT02367651Phase 2
- Phase II Study of Pazopanib and Topotecan in Cervical CancerWithdrawnNCT02348398Phase 2
- SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)WithdrawnNCT02342600Phase 2
- Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma MultiformeActive, not recruitingNCT02331498Phase 1/2
- Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC PatientsStatus unknownNCT02324803Phase 2
- A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell CancerWithdrawnNCT02307474Not applicable
- Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid TumoursCompletedNCT02303028Phase 1/2
- Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)TerminatedNCT02279576Phase 2
- Pazopanib Vs. Pazopanib Plus GemcitabineActive, not recruitingNCT02203760Phase 2
- Pazopanib for Metastatic Alveolar Soft Part SarcomaTerminatedNCT02113826Phase 2
- Optimizing Pazopanib Exposure in RCC PatientsTerminatedNCT02089802Phase 2
- Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid ChondrosarcomaCompletedNCT02066285Phase 2
- Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)CompletedNCT02014636Phase 1
- Combined Modality Treatment of Sarcomas of the ExtremitiesCompletedNCT01985295Phase 1
- A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue SarcomaCompletedNCT01861951Phase 2
- Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid CarcinomaCompletedNCT01813136Phase 2
- Pazopanib Maintenance for SCLCCompletedNCT01797874Phase 2
- Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the LungTerminatedNCT01759303Phase 2
- Pazopanib in Advanced and Cisplatin-resistant Germ Cell TumorsCompletedNCT01743482Phase 2
- Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue SarcomaCompletedNCT01719302Phase 1/2
- Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric CancerTerminatedNCT01716546Phase 1/2
- Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)CompletedNCT01716416Phase 1
- Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant TumorsCompletedNCT01713972Phase 1
- Pazopanib in Relapsed and Refractory Small Cell Lung CancerCompletedNCT01713296Phase 2
- Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney CancerActive, not recruitingNCT01684397Phase 1/2
- Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With PaclitaxelCompletedNCT01666418Phase 2
- Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian CancerCompletedNCT01644825Phase 2
- Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG CriteriaTerminatedNCT01642017Phase 1
- Phase I Study of MLN8237 and Pazopanib in Patients With Solid TumorsCompletedNCT01639911Phase 1
- Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.CompletedNCT01636908Not applicable
- Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)CompletedNCT01613846Phase 3
- [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian CancerCompletedNCT01608009Phase 1
- Pazopanib in Second-line Therapy in Renal Cell CarcinomaStatus unknownNCT01577784Phase 2
- Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5CompletedNCT01566747Phase 2
- Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid TumorsActive, not recruitingNCT01552356Phase 1
- Pazopanib or Pemetrexed and Crizotinib in Advanced CancerTerminatedNCT01548144Phase 1
- Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue SarcomaTerminatedNCT01543802Phase 2
- A Combination of Pazopanib and Carboplatin in Advanced Solid MalignanciesTerminatedNCT01542047Phase 1
- pazopanib_NCRCC,Ph2 STUDYCompletedNCT01538238Phase 2
- Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and SunitinibCompletedNCT01524848Phase 2
- First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell CarcinomaCompletedNCT01521715Phase 4
- Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell CarcinomaCompletedNCT01513187Phase 1/2
- FLO +/- Pazopanib as First-line Treatment in Advanced Gastric CancerCompletedNCT01503372Phase 2
- Dose Escalation Study of Pazopanib Plus TH-302CompletedNCT01485042Phase 1
- Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed UterineCompletedNCT01442662Phase 2
- Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and CholangiocarcinomaCompletedNCT01438554Phase 1
- Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss PatientsCompletedNCT01430572Phase 1
- Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By SurgeryCompletedNCT01413113Phase 1
- Rotating Pazopanib and Everolimus to Avoid ResistanceCompletedNCT01408004Phase 2
- Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid TumorsTerminatedNCT01407562Phase 1
- HYPAZ: Hypertension Induced by PazopanibTerminatedNCT01392352Phase 2
- Pazopanib, Docetaxel, Prednisone ProstateCompletedNCT01385228Phase 1
- Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaStatus unknownNCT01377298Phase 2
- Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is PossibleCompletedNCT01361334Phase 2
- Study of Pazopanib and Vorinostat in Patients With Advanced MalignanciesCompletedNCT01339871Phase 1
- Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)CompletedNCT01323400Phase 2
- Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian CancerCompletedNCT01262014Phase 2
- Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian CancerCompletedNCT01238770Phase 1/2
- Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)CompletedNCT01221506Early Phase 1
- Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START TrialActive, not recruitingNCT01217931Phase 2
- Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line ChemotherapyTerminatedNCT01208064Phase 2/3
- Pazopanib and Paclitaxel for Non-Small Cell Lung CancerWithdrawnNCT01179269Phase 2
- Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid TumorsCompletedNCT01165385Phase 1
- A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular DegenerationCompletedNCT01154062Phase 1
- A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid TumorsWithdrawnNCT01130623Phase 1
- Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine TumorCompletedNCT01099540Phase 2
- Temsirolimus and Pazopanib in Patients With Advanced Solid TumorsCompletedNCT01072890Phase 1
- A Safety Study to Evaluate Pazopanib Eye Drops in Healthy VolunteersCompletedNCT01072214Phase 1
- Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast CancerTerminatedNCT01060514Phase 1
- Phase II Pazopanib Study in Advanced DermatofibrosarcomasTerminatedNCT01059656Phase 2
- A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in HumansCompletedNCT01051700Phase 1
- Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to TreatmentCompletedNCT01031875Phase 2
- Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to TreatmentCompletedNCT00929903Phase 1
- Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung CancerCompletedNCT00866528Phase 1
- VEG111485: A QTc Study of PazopanibCompletedNCT00861029Phase 1